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Abstract: A number of natural and chemical compounds that exert anti-oxidative properties are
demonstrated to be beneficial for brain and cognitive function, and some are reported to reduce
the risk of dementia. However, the detailed mechanisms by which those anti-oxidative compounds
show positive effects on cognition and dementia are still unclear. An emerging body of evidence
suggests that the integrity of the cerebrovascular blood-brain barrier (BBB) is centrally involved in
the onset and progression of cognitive impairment and dementia. While recent studies revealed
that some anti-oxidative agents appear to be protective against the disruption of BBB integrity
and structure, few studies considered the neuroprotective effects of antioxidants in the context
of cerebrovascular integrity. Therefore, in this review, we examine the mechanistic insights of
antioxidants as a pleiotropic agent for cognitive impairment and dementia through a cerebrovascular
axis by primarily focusing on the current available data from physiological studies. Conclusively,
there is a compelling body of evidence that suggest antioxidants may prevent cognitive decline and
dementia by protecting the integrity and function of BBB and, indeed, further studies are needed to
directly examine these effects in addition to underlying molecular mechanisms.
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1. Introduction
As a consequence of rapidly aging populations, particularly in developed nations, dementia has
become a major health and medical issue imposing an extraordinary economic burden. As reported
by the World Health Organization and Alzheimer’s disease International, the global cost of
dementia-related healthcare was estimated to be $604 billion in 2010, which was equal to 1% of
world gross domestic product, indicating a significant socioeconomic impact [1]. Studies also predict
that this cost will greatly increase and is expected to double in the next 10–15 years. Indeed, the latest
estimated global cost of dementia in 2015 based on a meta-analysis was $818 billion, an increase of 35%
since 2010 [2]. Astoundingly, the estimated prevalence of dementia has increased from 35.6 million in
2010 to 46.8 million in 2015, an increase of 34% [2]. Clearly, there is an urgent necessity to establish
effective therapeutic strategies to delay or prevent the onset and progression of this disorder.
Major subtypes of dementia are Alzheimer’s disease (AD), vascular dementia, Lewy body
dementia, and frontotemporal dementia, which accounts for approximately 43%, 15%, 5% and 1%
of all dementia cases, respectively [3]. Although the pathology and pathogenesis of these disorders
remain largely unclear, it is increasingly recognized that the integrity of cerebrovasculature is critical
to the maintenance of healthy brain function and integrity [4]. The human brain ordinarily receives
20% of cardiac output despite its small volume (2% against total body mass), and the surface
area of cerebrovascular network available for molecular exchange between the brain and blood is
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approximately 20 m2 [5]. Dysfunctional cerebrovascular integrity allows blood-to-brain extravasation
of potentially neuroactive molecules, which thereafter trigger a neuroinflammatory cascade and
subsequently, activation of neuronal apoptosis pathways, conditions which lead to neurodegeneration
and if persisting, cognitive decline. Thus, it is highly plausible that subtle changes in cerebrovascular
permeability can have substantial impacts on the brain and neurocognitive function.
In recent clinical and animal model studies, agents with anti-oxidative properties are reported to
exert therapeutic effects on cognitive impairment and dementia [6–8]. However, whilst the majority
of these studies demonstrated the beneficial effects of antioxidants on cognitive function via direct
neuroprotective actions within the brain, no studies have implicated the efficacy of antioxidant therapy
through the cerebrovascular axis. Therefore, this review summarizes the current available data from
both animal and human studies to potentiate the role of antioxidants in the prevention of dementia and
cognitive decline via mechanisms mediated through the cerebrovascular axis. Moreover, considerations
for future studies examining the antioxidant effects on the cerebrovasculature are discussed.
2. Cerebrovascular Integrity in Neurodegeneration, Cognitive Decline and Dementia
The brain is a vital organ, yet extremely vulnerable to various endogenous and exogenous insults
such as viral and bacterial pathogens, inflammatory cells, pro-inflammatory cytokines, reactive oxygen
species (ROS), and macronutrients [5]. Therefore, in a healthy, non-pathological state, this organ is
protected from the peripheral circulation by a structurally unique neurovascular unit, which constitutes
the blood-brain barrier (BBB). The main feature of the BBB is a monolayer of endothelial cells that are
tightly opposed to one another, forming a physical barrier between the brain and blood. The cells
are fused each other by tight junctional and adheren junctional complexes, which consist of integral
membrane tight junction proteins including occludin and claudin, anchored by cytoplasmic zonula
occludens (ZO). This impermeable layer of endothelial cells is structurally supported by several
layers of underlying basement membranes as well as pericytes and astrocytic endfeet. A healthy,
functioning BBB strictly regulates molecular trafficking between the brain and blood, allowing only
highly specific transcellular transport of particular molecules that are essential to the brain, such as
glucose and oxygen. However, under certain pathological stress conditions, the integrity of this
highly selective barrier system can be transiently or chronically compromised depending on the
nature of the insults. The factors that can deteriorate BBB integrity and increase its permeability
include inflammation, oxidative stress, hypertension, stroke, HIV, lipids, smoking, alcohol intake,
mental stress, and lowered cerebral blood flow, although the underlying molecular mechanisms are
not fully understood [4,9,10].
2.1. Dysfunction of the Cerebrovascular Blood-Brain Barrier
A dysfunctional BBB may occur via (i) impaired transcellular transport, mainly due to
dysregulation of endothelial receptors and intracellular transporters; (ii) impaired paracellular
unspecific extravasation of molecules due to a loss of tight junction complex; and/or (iii) loss of
endothelial cells per se due to apoptosis or traumatic injury. Persistent disturbances of BBB allow
substantial cerebral extravasation of blood-borne potentially neurotoxic molecules, which thereby
promote the synthesis and release of pro-inflammatory cytokines resulting in the activation of
microglial phagocytes and production of ROS [11]. Chronically heightened inflammatory and oxidative
stress in the brain results in the production of toxic products that compromise cell function, alter cellular
phenotypes, damage DNA, and eventually lead to neuroinflammation and neurodegeneration.
The latter is increasingly suggested by a number of studies to be profoundly associated with the
pathogenesis and pathology of cognitive decline and dementia including AD and vascular dementia [5].
Indeed, neuroinflammation, microgliosis and mitochondrial dysfunction are commonly observed in
the brain of subjects with AD and vascular dementia [12–14].
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2.2. Blood-Brain Barrier Dysfunction in Cognitive Deficits and Dementia
Despite decades of attempts in Alzheimer’s research, anti-amyloid strategies have failed
to consistently deliver positive results in the prevention and treatment of AD [7,15]. In fact,
some neuropsychological and neuropathological characteristics of AD cannot be fully explained
by the amyloid hypothesis alone. For example, some studies report that the severity of amyloidosis
does not consistently correlate with the severity of AD, and the biosynthesis of β-amyloid in sporadic
AD subjects is comparable to otherwise healthy individuals [9,16,17].
Emerging evidence substantiates the involvement of cerebrovascular dysfunction in the
pathogenesis of AD and other dementias. In vivo and in vitro studies demonstrated that the transport
of β-amyloid across the BBB is mediated by receptor for advanced glycation endproducts [18,19]. Thus,
the dysregulation of such pathways is suggested to result in reduced β-amyloid clearance from the
brain, which may consequently induce amyloid plaque formation. The vascular risk factors have been
increasingly associated with heightened risk of dementia and AD, whereby a substantial body of work
has reported exaggerated BBB permeability in the brains of individuals with cognitive impairment or
dementia [4]. Post-mortem histological analyses revealed an accumulation of blood-borne proteins
including albumin, immunoglobulins, and fibrinogen within the parenchyme of hippocampal
formation and cortical regions of subjects with AD [20]. In addition, other post-mortem studies reported
degeneration of BBB pericytes and reduced endothelial tight junction protein expression in human AD
brain [21]. Further supportive evidence of BBB breakdown in individuals with AD and mild cognitive
impairment is provided by studies showing increased concentration of albumin in cerebrospinal fluid
relative to blood [22,23]. Moreover, signs of compromised BBB integrity are commonly reported in
animal models of AD, leading to loss of endothelial tight junction complex and cerebral extravasation
and accumulation of plasma derived macromolecules [9,24]. These data consistently implicate a strong
association between dysfunctional BBB and cognitive decline and dementia.
There has been rigorous debate on whether the breakdown of BBB is a primary causative factor of
neurodegeneration and dementia or whether it occurs as a downstream response [25]. An increasing
number of studies to date report that BBB disruption precedes neurodegeneration and cognitive decline
in clinical AD subjects, and in AD animal models, the appearance of hallmark pathophysiological
features such as amyloid plaques, strongly suggesting a causal link rather than a consequential
one [4]. Recent advances in neuroimaging and neurovascular imaging technologies using state-of-art
dynamic contrast-enhanced MRI now allow non-invasive evaluation of regional BBB permeability
in vivo with high sensitivity [26]. In 2016, an intriguing study from Maastricht University Medical
Center elegantly demonstrated the substantially increased permeability of BBB at a very early stage
of AD [27]. The study also revealed that the extent of BBB leakage positively associates with the
severity of cognitive decline measured by Mini-Mental State Examination. In addition to this recent
report, BBB breakdown was demonstrated to be evident in a murine model of AD Tg2576 mice as
early as 4 months of age, which was 10 months before the distinct formation of amyloid plaques at
14 months [28]. Moreover, a recent study in our laboratory demonstrated that substantial disruption of
BBB and neuroinflammation was observed prior to neurodegenerative changes and cognitive decline
in a dietary-induced mouse model of cognitive decline (unpublished observations by Takechi et al.).
Collectively, compelling evidence from experimental and clinical studies strongly indicate a causal
association between compromised BBB integrity and the onset and progression of cognitive dysfunction
and dementia.
3. Involvement of Oxidative Stress during Breakdown of the Blood-Brain Barrier
Oxidative stress is a state that arises from an inappropriate redox balance where the production
of ROS exceeds the conversion/neutralization of ROS into less toxic derivatives by antioxidants such
as glutathione and superoxide dismutase (SOD). ROS may be generated by several pathways, such as
conversion of oxygen into superoxide by enzymatic activities of oxidase or altered metal homeostasis
(Mn, Fe, Cu) and ensuing metal catalyzed free radical production through classic Fenton chemical
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pathways. Superoxide is frequently converted into hydrogen peroxide, the most bioactive and stable
form of ROS, however, superoxide may also react with nitric oxide generating additional free radicals.
In addition, hydrogen peroxides can also be generated directly by some enzymes such as NADPH
oxidase. Therefore, oxidative stress can occur by an overproduction of ROS by enzymes including
NADPH oxidase, and/or from lowered antioxidant levels or activity including SOD. Studies report
that elevated oxidative stress may have direct and indirect effects on the integrity of BBB [29].
An involvement of oxidative stress in the regulatory mechanisms of BBB integrity is supported
by a number of studies [29–32] (Figure 1). A study using SOD deficient mice demonstrated a
substantial breakdown of BBB allowing an extravasation of large blood-borne molecules into
the brain [33]. Lochhead et al. demonstrated that oxidative stress induced through a process of
hypoxia and reoxygenation in rats altered occludin structure and localization in cerebrovascular
endothelial cells [30]. Increased oxidative stress disrupted BBB by attenuating the expression of tight
junction proteins, ZO-1, occluding and claudin in diabetic mode rats [34]. In vitro studies confirmed
ROS-mediated modulation of BBB permeability occurs in a time- and concentration-dependent
manner [35,36]. Furthermore, Schreibelt et al. revealed in an in vitro model of BBB, ROS-induced
BBB disruption occurred through a loss of tight junction claudin-5 and occludin was mediated by
upregulated RhoA and PI3 kinase [37]. The study also for the first time reported the involvement
of protein kinase B/Akt in ROS-induced alteration of BBB tight junction expression and localization.
Moreover, a study using bovine brain microvascular endothelial cells indicated that increased
superoxide induced F-actin stress fiber formation through a Rho-dependent pathway [37]. ROS is
also documented to increase the expression of chemokine receptors, resulting in signaling flux and
phosphorylation of myosin light chain, which thereafter modulates actin structure [38]. The latter
findings are consistent with the cytoskeletal reorganization of BBB promoting the loss of BBB integrity.
Overall, the current literature implicates the substantial involvement of oxidative stress in BBB
dysfunction (Figure 1), and hence implies the pleiotropic effects of antioxidants in the protection of









by  a  number  of  studies  [29–32]  (Figure  1). A  study  using  SOD  deficient mice  demonstrated  a 




proteins, ZO‐1, occluding and claudin  in diabetic mode rats  [34]. In vitro stu i s confirmed ROS‐
mediated modulation of BBB permeability occurs  i  a time‐ and concentrati n‐dependent manner 
[35,36].  Furthermore,  Schreibelt  et  al.  revealed  in  an  in  vitro model  of  BBB,  ROS‐induced  BBB 
disruption  occurred  through  a  loss  of  tight  junction  claudin‐5  and  occludin  was mediated  by 
upregulated RhoA and PI3 kinase [37]. The study also for the first time reported the involvement of 
protein kinase B/Akt  in ROS‐induced alteration of BBB  tight  junction expression and  localization. 
Moreover,  a  study  using  bovine  brain  icrovascular  endothelial  cells  i icated  that  increased 
s peroxide induced F‐actin stress fib r formation through a Rho‐dependent pathway [37]. ROS is also 
documented  to  increase  the  expression  of  chemokine  receptors,  resulting  in  signaling  flux  and 
phosphorylation  of myosin  light  chain, which  thereafter modulates  actin  structure  [38]. The  latter 
findings are consistent with the cytoskeletal reorganization of BBB promoting the loss of BBB integrity. 









Studies  report  that oxidative  stress  is positively associated with  impaired cognitive  function 
[39,40]. Consistently, multiple  lines of  evidence demonstrate beneficial  effects  of  antioxidants on 
cognition  and  dementia  [8].  As  a  wealth  of  recent  evidence  suggests  that  BBB  dysfunction  is 
associated with the pathogenesis and pathology of neurodegeneration and the associated‐cognitive 
Figure 1. Involvement of oxidative stress in blood-brain barrier regulation. The diagram summarizes
the oxidative stress pathways that are involved in the regulation of blood-brain barrier integrity.
PI3K: phosphoinositide 3-kinase; RhoA: ras homolog gene family member A; ROS: reactive oxygen
species; ZO: zonnula occluden.
4. Antioxidants, Cognitive Decline and Blood-Brain Barrier
Studies report that oxidative stress is positively associated with impaired cognitive
function [39,40]. Consistently, multiple lines of evidence demonstrate beneficial effects of antioxidants
on cognition and dementia [8]. As a wealth of recent evidence suggests that BBB dysfunction is
associated with the pathogenesis and pathology of neurodegeneration and the associated-cognitive
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deficits, the preservation of BBB structure and function may offer an innovative and robust therapeutic
opportunity for cerebrovascular disorders. Whilst a number of studies have implicated antioxidant
therapy as a therapeutic option against cognitive decline, few studies have considered the positive
effects of antioxidants on cognition and dementia through a neurovascular axis. Therefore, in this
chapter, we will summarize the available literature that report the effects of antioxidants on BBB
integrity and cognition, and consider its use in dementia therapy through a cerebrovascular perspective
(refer to Table 1 for summary).
4.1. Anti-Oxidative Vitamins
A number of studies report that diet and nutrients have a strong association to the risk of dementia
including AD [41,42]. Vitamin A, C and E are known as potent anti-oxidants. In concert with the
substantial involvement of oxidative stress pathways in the pathophysiology of AD, studies found
that plasma and cerebrospinal fluid concentrations of Vitamins A and C were significantly lower in
patients with AD despite comparable dietary intake to healthy control subjects [43,44]. In a Rotterdam
study involving 5395 participants, high intake of dietary Vitamin C and Vitamin E was significantly
associated with lowered risk of AD and dementia [45,46]. A prospective population study with
4740 participants revealed that the use of Vitamin C and E supplements for more than 3 years
significantly reduced the risk of AD [47]. Furthermore, a randomized control trial by Li et al. showed
co-supplementation of Vitamin E and C with β-carotene (another well-established dietary antioxidant)
markedly improved cognitive function in otherwise healthy elderly individuals [48]. Consistent with
these clinical findings, an animal study reported that acute treatment with Vitamin C attenuates the
spatial learning and memory in APP/PSEN1 transgenic AD model mice and also in aged none-AD
wild-type mice [49]. However, in the same study, supplementation of Vitamin C did not alter cerebral
redox state, inflammation and amyloidosis, indicating that the anti-dementia effects of vitamins may
not only be attributed to its anti-oxidative properties. Indeed, Vitamin C has been reported to prevent
the oligomerization of Aβ [50]. An oral administration of Vitamin C is also reported to significantly
suppress cerebral oxidative damage in cerebral ischemia-reperfusion [51]. In addition, in vivo and
in vitro studies report that Vitamin A prevents neurodegeneration, and inhibits the formation of Aβ
fibrils, decreasing its aggregation and oligomerization [44,52].
It has been suggested that anti-oxidative vitamins may prevent cognitive decline also by protecting
BBB integrity. However, only a few studies have directly investigated the effects of anti-oxidative
vitamins on dementia through cerebrovascular axis. A study by Kook et al. recently reported that
high dose supplementation of Vitamin C reduced amyloidosis in the cortex and hippocampus of
AD mice (5XFAD) via attenuation of BBB disruption and mitochondrial alteration [53]. Vitamin C
is reported to prevent the disruption of BBB induced by compression of primary somatosensory
cortex by upregulating the expression of tight junction proteins, occludin and claudin-5 [54]. In a
model of stroke with substantial BBB disruption, a single injection of Vitamin C significantly reduced
BBB permeability [55]. Similarly, in a mouse model of cerebral ischemia, Vitamin C prevented BBB
dysfunction by protecting tight junction claudin-5 and attenuated edema and neuronal loss [56].
Moreover, an in vitro study provides supporting data that Vitamin C reversed hyperglycemia-mediated
BBB disruption [57]. Similar to Vitamin C, Vitamin E is also reported to prevent BBB breakdown
induced by oxidative stress by attenuation of endothelial oxidative stress and via increasing the
expression of tight junction proteins in vivo [58]. In rats with convulsion under hyperthermic
conditions, Vitamin E showed beneficial effects on modulation of BBB permeability [59]. Consistent
with the latter, ingestion of Vitamin E deficient diet in wild-type rats resulted in increased BBB
permeability and heightened oxidative stress [60].
Although the underlying mechanisms by which anti-oxidative vitamins protect BBB integrity
are largely unknown, these studies collectively suggest that these vitamins may ameliorate
neurodegenerative changes and cognitive decline by preserving the function and structure of BBB.
More direct experimental and clinical evidence would provide further strength to such hypotheses.
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Table 1. Literature summary.
Antioxidants Condition Study Type/Model Neuronal Measure(s) Blood-Brain BarrierMeasure(s) Others Reference No.
Vitamin C&E
cerebral ischemia mouse model ↓ neuronal loss ↑ claudin-5 [54]
AD mouse model (5XFAD) ↓ amyloid plaques ↓ BBB dysfunction [51]
BBB disruption mouse model N/A ↑ occludin, claudin-5 [52]
stroke rat model N/A ↓ BBB dysfunction [53]
hyperglycemia HBMEC N/A ↓ BBB dysfunction [55]
Vitamin E
Phospholipid transfer
protein deficient mouse model N/A ↑ occludin, claudin-5, ZO-1 [56]
healthy rats under hyperthermic convulsion N/A ↓ BBB dysfunction [57]
healthy rats with Vitamin E deficient diet N/A ↓ BBB dysfunction [58]
Melatonin
hypobaric hypoxia rats ↑ cognitive function; ↓ neuronalloss, neuroinflammation ↓ BBB dysfunction [61]
inflammation rat brain microvascular endothelial cells N/A ↑ ZO-1 [62]
oxidative stress bEnd.3 cells N/A ↑ claudin-5; ↓ cell death [63]
α-Lipoic acid
high-fat diet mouse model ↓ neuroinflammation ↓ BBB dysfunction [64]
ischemic stroke rat model ↓ neurological deficit,neuroinflammation ↓ BBB dysfunction [65]
Aged garlic
extract high-fat diet mouse model ↓ neuroinflammation ↓ BBB dysfunction [64]
Apocynin
BBB disruption rat perfusion model N/A ↓ BBB dysfunction improvedvascular tone [66]
BBB disruption HBMEC N/A ↓ BBB dysfunction ↑ AMPKactivation [67]
BBB disruption HBMEC N/A ↑ occludin, claudin-5 ↑ AMPKactivation [68]
Baicalein intracerebralhemorrhage rat model ↓ neurological deficit ↑ ZO-1 [69]
Caffein
Parkinson’s disease mouse model N/A ↑ occludin, ZO-1 [70]
AD rabbit model ↓ neuroinflammation ↑ occludin, ZO-1 [71]
Nutrients 2016, 8, 828 7 of 18
Table 1. Cont.





neuroinflammation ↓ BBB dysfunction [72]
cerebral ischemia rat model ↓ neurological deficit ↓ BBB dysfunction ↓ infarctvolume [73]
N/A BMEC N/A ↓ platelet recruitment [74]
Pinocembrin
cerebral ischemia rat model ↓ neurological deficit ↓ BBB dysfunction ↓ brain edema [75]






↑ occludin, ZO-1, claudin-5;
↓ ICAM-1, VCAM-1 [77]
BBB disruption HBMEC ↓ oxidative stress ↓ BBB dysfunction [78]
AD rat model ↓ neuroinflammation, β-amyloid ↑ claudin-5 [79]
cerebral ischemia rat model ↓ neuronal loss ↓ BBB dysfunction ↓ brain edema [80]
high-fat diet mouse model ↓ neuronal loss ↑ occludin, ZO-1 [81]
Tanshinone IIA
autoimmune
encephalomyelititis mouse model ↓ neuroinflammation ↑ occludin, claudin-5, ZO-1 [82]
hypoxia HBMEC N/A ↑ ZO-1 [83]
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Statin
AD in vitro BBB model N/A ↓ BBB dysfunction [85]
high-fat diet mouse model N/A ↓ BBB dysfunction [86]
Probucol high-fat diet mouse model ↓ neuroinflammation ↓ BBB dysfunction [87,88]
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Ibuprofen high-fat diet mouse model N/A ↓ BBB dysfunction [86]
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4.2. Other Natural Antioxidants
Melatonin is a neurohormone found in animals, plants and bacteria, reported to exhibit strong
anti-oxidative properties through protecting the mitochondrial membrane potential and thereby
suppressing the production of superoxides [91,92]. Melatonin is approved by the FDA as a dietary
supplement and readily available over the counter, commonly prescribed for treatment of insomnia.
Studies report that plasma melatonin levels are significantly decreased in subjects with AD, showing a
negative association with cognitive function, and a significant reduction is found even in healthy
elderly [93–95]. In a rat model of sporadic AD, melatonin was demonstrated to prevent memory loss
by attenuating amyloidosis and neurodegeneration [96]. Furthermore, in aged 22-month old wild-type
mice with significantly impaired spatial cognition, melatonin improved cognitive performance
by reducing cerebral amyloid burden through altered protein-cleaving secretase expression [97].
In addition, some studies showed that melatonin promotes hippocampal neuroplasticity and stimulates
the proliferation and differentiation of neural stem cells in vitro and in vivo [98–100]. A number of
studies have also demonstrated protective effects of melatonin on the BBB. A study by Vornicescu
et al. demonstrated that melatonin administration prevents oxidative stress-induced breakdown of
BBB and improves cognitive function [61]. In this study, a significant reduction in neuronal death and
neuroinflammation was also observed in melatonin treated rats. In vitro studies further investigated
mechanistic insights into the BBB protective effects of melatonin. A study using rat brain microvascular
endothelial cells revealed that BBB disruption induced by inflammation was completely prevented
by melatonin treatment via restoration of the expression of BBB tight junction ZO-1 and inhibiting
matrix metalloproteinase-9 [62]. Similarly, in a bEnd.3 cell line model of oxidative stress-induced
BBB dysfunction, treatment with melatonin prevented cell death and degradation of tight junction
proteins by activating Akt and suppressing phosphorylation of JNK [63]. Overall, the data presented
strongly suggests that melatonin may exert neuroprotective effects partially, if not entirely, through the
protection of BBB from oxidative and inflammatory stressors.
α-Lipoic acid (ALA) is known to chelate transition metals and ROS, thus inhibiting hydroxyl
radical formation. A clinical trial involving 43 AD patients over an observation period of 2 years
demonstrated that subjects receiving ALA showed constant scores in two neuropsychological tests,
while the untreated subjects showed significant decline in cognitive function [101]. Consistent with
the latter, in a rat model of vascular dementia, ALA significantly restored cognitive functioning
concomitant with markedly reduced ROS and malondialdehyde production and increased reduced
glutathione levels in the hippocampal formation, the domain crucial to learning and memory [102].
Increased acetylcholine and choline acetyltransferase levels as well as decreased acetylcholinesterase
activity were also observed in the hippocampus of ALA-treated rats. By using a murine model
of accelerated ageing, senescence accelerated mouse prone-8, ALA was demonstrated to improve
memory and supress oxidative stress during normal ageing [103]. However, few studies to date have
directly considered BBB permeability in context of the neuroprotective properties of ALA. Takechi et al.
reported in a dietary induced mouse model of BBB dysfunction, ALA preserved the integrity of BBB
by inhibiting oxidative stress, which resulted in the prevention of blood-to-brain protein extravasation
and significant attenuation of neuroinflammation [64]. Similarly, ALA was reported to ameliorate BBB
disruption, neuroinflammation and neurological motor deficits in a rat model of ischemic stroke [65].
Although these studies strongly suggest that ALA may prevent cognitive decline through the protection
of BBB, further studies are needed to directly investigate such association.
Another emerging potentially neuroprotective antioxidant is garlic. An extract of garlic contains a
mixture of biologically active compounds such as S-allylcysteine (SAC) and S-allylmercaptocysteine,
which are known to exert strong anti-oxidative effects. These compounds have repeatedly been
shown to provide antioxidant action by scavenging ROS, enhancing SOD, catalase glutathione
peroxidase, and increasing glutathione. A number of studies demonstrated the neuroprotective
effects of garlic [104]. Although clinical evidence is limited, Chauhan et al. elegantly demonstrated
the beneficial effects of garlic extracts in AD models [105]. In a study using Alzheimer’s Tg2576 mice
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supplemented with either aged garlic extract (AGE), SAC, or di-allyl-disulphide (DADS) for 4 months,
mice treated with AGE as well as mice treated with SAC or DADS showed substantially lower
cerebral amyloidosis compared to untreated mice [106]. Similarly, AGE, SAD and DADS significantly
attenuated neuroinflammation and tau protein. The extent of the neuroprotective effects reported were
ranked from AGE > SAC > DADS. Furthermore, a study using TgCRND8 AD model mice revealed that
the provision of AGE improved hippocampal-dependent cognition and memory [107]. Additionally,
in a study by Takechi et al., the cerebrovascular-protective effects of AGE via its anti-oxidative
properties were demonstrated in a mouse model of BBB dysfunction, which coincided with significant
attenuation of neuroinflammation [64]. In vitro and in vivo studies confirmed that the pleiotropic
effects of garlic extracts may be attributed to its anti-oxidative action on neurons, including sympathetic
neurons, preventing ROS-mediated oxidative insults [108]. The studies also revealed that SAC was the
most potent neuroprotective compound in AGE [108]. The data collectively suggests that AGE, or its
anti-oxidative components, may exert neuroprotective effects through various pathways including
direct anti-oxidative protection of neuronal cells as well as the preservation of BBB integrity.
There are other natural antioxidants that are recently reported to exhibit potent BBB protective
effects. These include apocynin [66–68], baicalein [69], caffeine [70,71,109], curcumin [72–74],
niacin [64], nicotine [64], pinocembrin [75,76,110], resveratrol [77–81,111], polyphenols [112],
and tanshinone IIA [82–84]. However, the number of studies investigating the effects of these agents
on neurodegeneration and cognitive performance is limited. Further investigations to support the
use of these agents for dementia prevention by focussing on the neurovascular integrity need to
be conducted.
4.3. Lipid-Lowering Drugs with Anti-Oxidative Properties
Many clinical drugs for treatment of cardiovascular disease exert antioxidant effects. Statins,
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are reported to show anti-oxidative
properties by inhibiting the increase of 8-isoprostane and suppressing the activity of nitric oxide
synthase [113,114]. While its effects on dementia are still controversial [115–117], case control and
retrospective population studies indicate that statins significantly reduce the risk of dementia and
cognitive impairment [118]. A 7-year follow-up study, the Rotterdam Study, revealed that statin
users have a 43% lower incidence of AD [119]. A number of putative underlying mechanisms for
statin’s neuroprotective effects are suggested [120]. Studies in humans and animal models showed
that statins attenuate cerebral amyloidosis in AD [121,122]. Other studies showed that cerebral
oxidative stress and the production of pro-inflammatory cytokines were reduced by atorvastatin in
animal models of AD [123,124]. An emerging body of recent studies also suggests statins’ therapeutic
potential for AD via protection of the neurovascular unit [125]. In a transgenic mouse model of AD,
atorvastatin and pitavastatin improved memory and reduced amyloidosis and neuroinflammation
by modulating the permeability of BBB. Similarly, simvastatin was shown to protect BBB integrity
and attenuate neuropathophysiology and oxidative stress in APP transgenic AD mice [126]. In line
with the latter, an in vitro study using human cerebral microvascular endothelial cells showed that
simvastatin and lovastatin attenuated Aβ-induced BBB dysfunction [85]. Moreover, in a mouse
model of dietary- induced BBB dysfunction, we demonstrated that atorvastatin and pravastatin
reversed the disruption of BBB integrity [86]. Interestingly, all studies indicated here reported
the BBB protective effects of statins independent of their lipid-lowering effects but rather occurred
concomitant with attenuated oxidative stress, suggesting its cerebrovascular protective action through
anti-oxidative pathways.
Probucol is a conventional cholesterol-lowering drug that possesses potent anti-oxidative
properties, which attribute to attenuation of ROS by inhibiting the expression of Nox2 [127], and by
increasing glutathione peroxidase activity [128]. A limited number of clinical trials report that probucol
stabilizes cognitive function in AD [129]. Consistent with this notion, a study reported in a mouse
model of cognitive and hippocampal synaptic impairment induced by an intracerebroventricular
Nutrients 2016, 8, 828 10 of 18
injection of aggregated Aβ1-40, probucol prevented hippocampal lipid peroxidation and attenuated
loss of hippocampal-dependent learning and memory [130]. Similarly, in a mouse model of
streptozotocin-induced cognitive impairment, probucol improved cognitive function by attenuating
hippocampal oxidative stress [131]. Consistent with the hypothesis, studies in our laboratory reported
that probucol prevented the disruption of BBB and neuroinflammation induced by an ingestion of a
high-fat diet in mice [87,88]. These studies also revealed that the BBB protective effects of probucol
was through its anti-oxidative effects by attenuating cerebral oxidative stress and neurovascular
inflammation. A study by Russell et al. further supports this data by showing improved vascular
endothelial function in a model of atherosclerosis by administration of probucol, independent of its
cholesterol-lowering effects [132].
Fenofibrate is another lipid-lowering drug reported to lower cholesterol and triglycerides and
increase HDL-cholesterol [133]. Besides its anti-atherosclerotic effects, fenofibrate is reported to exert
anti-oxidative effects by reducing lipid peroxidation and increasing antioxidants including glutathione,
in a rat model of Parkinson’s disease [134]. Interestingly, in the same study by Uppalapati et al.,
fenofibrate attenuated neurodegeneration and improved cognitive function in a dose-dependent
manner [134]. Consistently, in a brain irradiation-induced mouse model of cognitive impairment,
fenofibrate significantly improved cognitive performance [135]. However, the clinical evidence of
fenofibrate on cognitive function and dementia is limited [136]. In a murine model of BBB dysfunction
induced by HIV Tat protein, Huang et al. demonstrated that fenofibrate attenuated BBB permeability,
neuroinflammation and neurodegeneration [89]. Moreover, an in vitro study using mouse cerebral
capillary endothelial cells showed that fenofibric acid (an active metabolite of fenofibrate) protected
BBB integrity from oxygen-glucose deprivation-induced BBB hyper-permeability [90]. However,
no studies to date have considered the neuroprotective effects of fenofibrate through modulation of
BBB-specific pathways.
These studies suggest that the lipid-lowering pharmacological agents with anti-oxidative
properties exert positive effects on neurodegeneration and cognitive deficits, at least in part,
through protective mechanisms via the BBB. Further studies to identify more detailed molecular
and cellular mechanisms to strengthen this evidence are required.
4.4. Other Pharmacological Agents with Anti-Oxidative Effects
There are several other pharmacological agents with anti-oxidative properties exerting vascular
protective effects, and some are demonstrated to be beneficial for BBB. Ibuprofen is a widely
utilized nonsteroidal anti-inflammatory drug (NSAID) reported to non-selectively attenuate the
activity of cyclooxygenase and is reported to exert substantial oxidative effects [137]. A number
of epidemiological and clinical studies reported that the use of ibuprofen and other NSAIDs delayed
the onset and progression of AD [138,139]. Although the mechanisms by which NSAIDs reduce the
risk of AD are yet to be elucidated, both in vivo and in vitro studies showed that NSAIDs including
ibuprofen, flurbiprofen, indomethacin and sulindac, significantly attenuated the cerebral production
and accumulation of Aβ [140] and suppressed neuroinflammation [141]. Combination therapy of
ibuprofen with lipoic acid was also reported to show neuroprotective effects in a rat model of
AD [142]. A recent study revealed significant alterations in protein and phosphoprotein expression
including heat shock protein 8, dihydropyrimidinase-related protein 2 and γ-enolase, within the
hippocampal formation [143]. In addition, a recent study reported that ibuprofen prevents the decrease
of N-acetylaspartate and atrophy of hippocampal formation in a transgenic mouse model of AD via
MRI neuroimaging and spectroscopy analysis [144]. However, none of these studies considered the
effect of ibuprofen on cerebrovascular integrity. To our best knowledge, the only study demonstrating
BBB modulating effects of ibuprofen is that by Pallebage-Gamarallage et al. [86]. The study reported
novel findings in which ibuprofen treatment for 1 or 3 months can restore the compromised BBB
integrity in a high fat-induced BBB dysfunction mouse model. Clearly, further investigation is necessary
to elucidate the BBB protective role of ibuprofen in cognition and dementia.
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5. Conclusions
Previous studies suggest that natural and chemical compounds with anti-oxidative properties
have beneficial effects on neuroprotection and cognitive performance, although the underlying
mechanisms are largely unknown. As summarized in the current review, clinical evidence suggests the
therapeutic effects of antioxidants on dementia and cognitive impairment and findings from animal
and in vitro studies support this evidence. Furthermore, a substantial body of evidence from animal
and in vitro studies suggests that such neuroprotective effects of antioxidants may be entirely or
partially attributed to the BBB protective effects of antioxidants. However, the number of studies
directly considering the therapeutic effects of antioxidants on cognitive impairment through the axis of
cerebrovascular BBB integrity remain limited. Further investigations should focus on simultaneously
testing the neuroprotective effects as well as the BBB protective effects of antioxidants. Furthermore,
the elucidation of such mechanisms may lead to the development and search for new agents to
specifically target the protection of BBB, conferring neuroprotection.
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